Interpretation of updated NCCN guidelines for non-small cell lung cancer (version 1. 2021)
- VernacularTitle:2021年V1版《NCCN非小细胞肺癌临床诊治指南》更新解读
- Author:
Jiahao ZHANG
1
;
Yajie ZHANG
1
;
Jie WANG
2
;
Hecheng LI
1
Author Information
1. Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, P.R.China
2. Medical Oncology Department, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, 100021, P.R.China
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
NCCN guidelines;
updates of version 1, 2021;
interpretation of guideline
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(03):271-277
- CountryChina
- Language:Chinese
-
Abstract:
Based on new clinical evidence, the National Comprehensive Cancer Network (NCCN) annually updates and releases the "NCCN Guidelines for the Clinical Diagnosis and Treatment of Non-Small Cell Lung Cancer" which has become the reference for clinical diagnosis and treatment approved and complied by clinicians worldwide. On November 25, 2020, the latest 2021 V1 version of "NCCN Clinical Diagnosis and Treatment Guidelines for Non-Small Cell Lung Cancer" (hereinafter referred to as "Guidelines") was released. Compared with the 8th edition of the "Guidelines" in 2020, many updates focused on the progress of targeted and immunotherapy. This article will provide the interpretations of the updated therapy content of this edition of the guidelines.
